Older patients with chronic myeloid leukemia (a parts per
thousand yen65 years) profit more from higher imatinib doses
than younger patients: a subanalysis of the randomized
CML-Study IV

J 2014

Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

PROETEL, U, N PLETSCH, M LAUSEKER, M C MULLER, B HANFSTEIN et. al.

Základní údaje

Originální název

Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Autoři

Vydání

Annals of hematology, New York, Springer Verlag, 2014, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.634

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00277-014-2041-0

UT WoS

000337144900009

Klíčová slova anglicky

Chronic myeloid leukemia; Older patients; Different imatinib dose regimens; Early applied higher imatinib dosages

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 9. 2020 09:23, Mgr. Tereza Miškechová

Anotace

V originále

The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (a parts per thousand yen65 years vs. < 65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were a parts per thousand yen65 years. The median dose per day was lower for patients a parts per thousand yen65 years on IM800, with the highest median dose in the first year (466 mg/day for patients a parts per thousand yen65 years vs. 630 mg/day for patients < 65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874.

Citovat

PROETEL, U, N PLETSCH, M LAUSEKER, M C MULLER, B HANFSTEIN, SW KRAUSE, L KALMANTI, A SCHREIBER, D HEIM, GM BAERLOCHER, WK HOFMANN, E LANGE, H EINSELE, M WERNLI, S KREMERS, R SCHLAG, L MULLER, M HANEL, H LINK, B HERTENSTEIN, M PFIRRMANN, A HOCHHAUS, J HASFORD, R HEHLMANN a S SAUSSELE. Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of hematology. New York: Springer Verlag, 2014, roč. 93, č. 7, s. 1167-1176. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-014-2041-0.

@article{1681541,
   author = {Proetel, U and Pletsch, N and Lauseker, M and Muller, M C and Hanfstein, B and Krause, SW and Kalmanti, L and Schreiber, A and Heim, D and Baerlocher, GM and Hofmann, WK and Lange, E and Einsele, H and Wernli, M and Kremers, S and Schlag, R and Muller, L and Hanel, M and Link, H and Hertenstein, B and Pfirrmann, M and Hochhaus, A and Hasford, J and Hehlmann, R and Saussele, S and Žáčková, Daniela},
   article_location = {New York},
   article_number = {7},
   doi = {http://dx.doi.org/10.1007/s00277-014-2041-0},
   keywords = {Chronic myeloid leukemia; Older patients; Different imatinib dose regimens; Early applied higher imatinib dosages},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV},
   volume = {93},
   year = {2014}
}

TY  - JOUR
ID  - 1681541
AU  - Proetel, U - Pletsch, N - Lauseker, M - Muller, M C - Hanfstein, B - Krause, SW - Kalmanti, L - Schreiber, A - Heim, D - Baerlocher, GM - Hofmann, WK - Lange, E - Einsele, H - Wernli, M - Kremers, S - Schlag, R - Muller, L - Hanel, M - Link, H - Hertenstein, B - Pfirrmann, M - Hochhaus, A - Hasford, J - Hehlmann, R - Saussele, S - Žáčková, Daniela
PY  - 2014
TI  - Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
JF  - Annals of hematology
VL  - 93
IS  - 7
SP  - 1167-1176
EP  - 1167-1176
PB  - Springer Verlag
SN  - 09395555
KW  - Chronic myeloid leukemia
KW  - Older patients
KW  - Different imatinib dose regimens
KW  - Early applied higher imatinib dosages
N2  - The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (a parts per thousand yen65 years vs. < 65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were a parts per thousand yen65 years. The median dose per day was lower for patients a parts per thousand yen65 years on IM800, with the highest median dose in the first year (466 mg/day for patients a parts per thousand yen65 years vs. 630 mg/day for patients < 65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874.
ER  -

PROETEL, U, N PLETSCH, M LAUSEKER, M C MULLER, B HANFSTEIN, SW KRAUSE, L KALMANTI, A SCHREIBER, D HEIM, GM BAERLOCHER, WK HOFMANN, E LANGE, H EINSELE, M WERNLI, S KREMERS, R SCHLAG, L MULLER, M HANEL, H LINK, B HERTENSTEIN, M PFIRRMANN, A HOCHHAUS, J HASFORD, R HEHLMANN a S SAUSSELE. Older patients with chronic myeloid leukemia (a parts per thousand yen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. \textit{Annals of hematology}. New York: Springer Verlag, 2014, roč.~93, č.~7, s.~1167-1176. ISSN~0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-014-2041-0.

Podrobný výpis o publikaci